Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746798 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 479
- Enrollment target
NCT00746798: Completed Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00746798 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 479 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (260% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00746798, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 479 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
Primary Outcome
Antibodies to the vaccine antigens were measured by the Plaque Reduction Neutralization Test.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ChimeriVax-WN02 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00746798 record still lists
NCT00746798 is an interventional study that assigns participants to a tested intervention. The registered 479 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (260% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00746798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00746798 about?
NCT00746798 is a clinical study titled "Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults". The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
What is the current status of trial NCT00746798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 479 participants. The study started on 2008-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00746798?
The interventions under investigation include: Placebo (BIOLOGICAL), ChimeriVax-WN02 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00746798?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00746798's enrollment target sits among peer trials
479 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia